FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2148375003> ?p ?o ?g. }

• W2148375003 endingPage "2852" @default.
• W2148375003 startingPage "2844" @default.
• W2148375003 abstract "Abstract This phase I trial examined the safety, pharmacokinetics, and pharmacodynamics of MLN8054, an oral, selective, small-molecule inhibitor of Aurora A kinase. Patients with advanced solid tumors received increasing doses of MLN8054 in 28-day cycles until dose-limiting toxicity (DLT) was seen in ≥2 of 3-6 patients in a cohort. For the 10-mg and 20-mg cohorts, treatment was administered once daily on days 1 to 5 and 8 to 12. Patients in later cohorts (25, 35, 45, 55, 60, 70, and 80 mg/day) were treated four times daily on days 1 to 14, with the largest dose at bedtime (QID-14D) to mitigate benzodiazepine-like effects possibly associated with peak plasma concentrations. Patients (n = 43) received a median of 1 cycle (range, 1–10). DLT of somnolence was first noted in the 20-mg cohort. Two DLTs of somnolence (n = 1) and transaminitis (n = 1) were seen at QID-14D 80 mg. Grade 2 oral mucositis (n = 1), predicted to be a mechanistic effect, was observed only at QID-14D 80 mg. MLN8054 exposure levels were roughly linear with dose; terminal half-life was 30 to 40 hours. Pharmacodynamic analyses of skin and tumor mitotic indices, mitotic cell chromosome alignment, and spindle bipolarity provided evidence of Aurora A inhibition. MLN8054 dosing for 10 to 14 days in 28-day cycles was feasible. Somnolence and transaminitis were DLTs. Pharmacodynamic analyses in mitotic cells of both skin and tumor provided proof of mechanism for Aurora A kinase inhibition. A more potent, selective, second-generation Aurora A kinase inhibitor, MLN8237, is in clinical development. Mol Cancer Ther; 9(10); 2844–52. ©2010 AACR." @default.
• W2148375003 created "2016-06-24" @default.
• W2148375003 creator A5002429045 @default.
• W2148375003 creator A5002656825 @default.
• W2148375003 creator A5003610011 @default.
• W2148375003 creator A5011012477 @default.
• W2148375003 creator A5015190461 @default.
• W2148375003 creator A5016108968 @default.
• W2148375003 creator A5026551753 @default.
• W2148375003 creator A5027501007 @default.
• W2148375003 creator A5037247287 @default.
• W2148375003 creator A5053953098 @default.
• W2148375003 creator A5055862157 @default.
• W2148375003 creator A5069781389 @default.
• W2148375003 creator A5079316267 @default.
• W2148375003 creator A5082191671 @default.
• W2148375003 creator A5083582948 @default.
• W2148375003 creator A5087385450 @default.
• W2148375003 creator A5090670345 @default.
• W2148375003 creator A5091727687 @default.
• W2148375003 date "2010-10-01" @default.
• W2148375003 modified "2023-10-17" @default.
• W2148375003 title "Phase I Study of the Selective Aurora A Kinase Inhibitor MLN8054 in Patients with Advanced Solid Tumors: Safety, Pharmacokinetics, and Pharmacodynamics" @default.
• W2148375003 cites W1556655356 @default.
• W2148375003 cites W1970675560 @default.
• W2148375003 cites W1979849831 @default.
• W2148375003 cites W2012618476 @default.
• W2148375003 cites W2035179505 @default.
• W2148375003 cites W2052672292 @default.
• W2148375003 cites W2060747696 @default.
• W2148375003 cites W2064261028 @default.
• W2148375003 cites W2098517908 @default.
• W2148375003 cites W2116565287 @default.
• W2148375003 cites W2121169754 @default.
• W2148375003 cites W2122742535 @default.
• W2148375003 cites W2126005827 @default.
• W2148375003 cites W2126572395 @default.
• W2148375003 cites W2139248078 @default.
• W2148375003 cites W2160475600 @default.
• W2148375003 cites W2276451490 @default.
• W2148375003 doi "https://doi.org/10.1158/1535-7163.mct-10-0299" @default.
• W2148375003 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20724522" @default.
• W2148375003 hasPublicationYear "2010" @default.
• W2148375003 type Work @default.
• W2148375003 sameAs 2148375003 @default.
• W2148375003 citedByCount "77" @default.
• W2148375003 countsByYear W21483750032012 @default.
• W2148375003 countsByYear W21483750032013 @default.
• W2148375003 countsByYear W21483750032014 @default.
• W2148375003 countsByYear W21483750032015 @default.
• W2148375003 countsByYear W21483750032016 @default.
• W2148375003 countsByYear W21483750032017 @default.
• W2148375003 countsByYear W21483750032018 @default.
• W2148375003 countsByYear W21483750032019 @default.
• W2148375003 countsByYear W21483750032020 @default.
• W2148375003 countsByYear W21483750032021 @default.
• W2148375003 countsByYear W21483750032022 @default.
• W2148375003 countsByYear W21483750032023 @default.
• W2148375003 crossrefType "journal-article" @default.
• W2148375003 hasAuthorship W2148375003A5002429045 @default.
• W2148375003 hasAuthorship W2148375003A5002656825 @default.
• W2148375003 hasAuthorship W2148375003A5003610011 @default.
• W2148375003 hasAuthorship W2148375003A5011012477 @default.
• W2148375003 hasAuthorship W2148375003A5015190461 @default.
• W2148375003 hasAuthorship W2148375003A5016108968 @default.
• W2148375003 hasAuthorship W2148375003A5026551753 @default.
• W2148375003 hasAuthorship W2148375003A5027501007 @default.
• W2148375003 hasAuthorship W2148375003A5037247287 @default.
• W2148375003 hasAuthorship W2148375003A5053953098 @default.
• W2148375003 hasAuthorship W2148375003A5055862157 @default.
• W2148375003 hasAuthorship W2148375003A5069781389 @default.
• W2148375003 hasAuthorship W2148375003A5079316267 @default.
• W2148375003 hasAuthorship W2148375003A5082191671 @default.
• W2148375003 hasAuthorship W2148375003A5083582948 @default.
• W2148375003 hasAuthorship W2148375003A5087385450 @default.
• W2148375003 hasAuthorship W2148375003A5090670345 @default.
• W2148375003 hasAuthorship W2148375003A5091727687 @default.
• W2148375003 hasBestOaLocation W21483750031 @default.
• W2148375003 hasConcept C111113717 @default.
• W2148375003 hasConcept C112705442 @default.
• W2148375003 hasConcept C121608353 @default.
• W2148375003 hasConcept C126322002 @default.
• W2148375003 hasConcept C197934379 @default.
• W2148375003 hasConcept C20552341 @default.
• W2148375003 hasConcept C2777288759 @default.
• W2148375003 hasConcept C2778496288 @default.
• W2148375003 hasConcept C2779034229 @default.
• W2148375003 hasConcept C29537977 @default.
• W2148375003 hasConcept C29730261 @default.
• W2148375003 hasConcept C71924100 @default.
• W2148375003 hasConcept C98274493 @default.
• W2148375003 hasConceptScore W2148375003C111113717 @default.
• W2148375003 hasConceptScore W2148375003C112705442 @default.
• W2148375003 hasConceptScore W2148375003C121608353 @default.
• W2148375003 hasConceptScore W2148375003C126322002 @default.
• W2148375003 hasConceptScore W2148375003C197934379 @default.
• W2148375003 hasConceptScore W2148375003C20552341 @default.
• W2148375003 hasConceptScore W2148375003C2777288759 @default.

• next